Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | GRIN2B | Q13224 | 10/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.50 |
| ▸ | MMP1 | P03956 | 2/20 | 0.50 |
| ▸ | MMP3 | P08254 | 2/20 | 0.50 |
| ▸ | MMP7 | P09237 | 2/20 | 0.50 |
| ▸ | MMP9 | P14780 | 2/20 | 0.50 |
| ▸ | MMP13 | P45452 | 1/20 | 0.50 |
| ▸ | MMP2 | P08253 | 1/20 | 0.48 |
| ▸ | MMP8 | P22894 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3443323 | 1.00 | SMN1; SMN2 (0.55) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL3443325 | 1.00 | SMN1; SMN2 (0.55) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL4274599 | 0.93 | SMN1; SMN2 (0.50) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL3444835 | 0.93 | SMN1; SMN2 (0.50) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL460173 | 0.93 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL4096075 | 0.90 | SMN1; SMN2 (0.50) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL28563410 | 0.87 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL21939748 | 0.87 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL5121088 | 0.86 | PDE4B (0.44) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL5452029 | 0.86 | GRIN2B (0.53) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12304907-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2025-05-20 | — | — | US | disclosed |
| US-12264154-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| US-20240279219-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-08-22 | — | — | US | disclosed |
| CN-116568677-A | piperidin-1-yl-N-pyridin-3-yl-2-oxoacetamide derivatives useful for the treatment of MTAP deficiency and/or MTA accumulating cancers | 探戈医药股份有限公司 | 2023-08-08 | — | — | CN | disclosed |
| EP-4188920-A1 | PIPERIDIN-1-YL-N-PYRYDINE-3-YL-2-OXOACETAMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF MTAP-DEFICIENT AND/OR MTA-ACCUMULATING CANCERS | Tango Therapeutics, Inc. (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20230113778-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2023-04-13 | — | — | US | disclosed |
| US-11492350-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2022-11-08 | — | — | US | disclosed |
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2022-04-28 | — | — | US | disclosed |
| CN-112094264-A | Hepatitis B core protein modulators | 组装生物科学股份有限公司 | 2020-12-18 | — | — | CN | disclosed |
| CN-108347943-B | Hepatitis B core protein modulators | 组装生物科学股份有限公司 | 2020-07-10 | — | — | CN | disclosed |
| US-20090258901-A1 | LIGANDS FOR MONOAMINE RECEPTORS AND TRANSPORTERS, AND METHODS OF USE THEREOF | AQUILA BRIAN M | 2009-10-15 | — | — | US | disclosed |
| US-20090258901-A1 | LIGANDS FOR MONOAMINE RECEPTORS AND TRANSPORTERS, AND METHODS OF USE THEREOF | AQUILA BRIAN M | 2009-10-15 | — | — | US | disclosed |
| US-7517892-B2 | Ligands for monoamine receptors and transporters, and methods of use thereof | SEPRACOR INC. (US) | 2009-04-14 | — | — | US | disclosed |
| US-7517892-B2 | Ligands for monoamine receptors and transporters, and methods of use thereof | SEPRACOR INC. (US) | 2009-04-14 | — | — | US | disclosed |
| US-7294637-B2 | Method of treating addiction or dependence using a ligand for a monamine receptor or transporter | SEPRACOR, INC. (US) | 2007-11-13 | — | — | US | disclosed |
| US-7294637-B2 | Method of treating addiction or dependence using a ligand for a monamine receptor or transporter | SEPRACOR, INC. (US) | 2007-11-13 | — | — | US | disclosed |
| US-7132551-B2 | Ligands for monoamine receptors and transporters, and methods of use thereof | SEPRACOR INC. (US) | 2006-11-07 | — | — | US | disclosed |
| US-20050080078-A1 | Method of treating addiction or dependence using a ligand for a monoamine receptor or transporter | SEPRACOR, INC. (US) | 2005-04-14 | — | — | US | disclosed |
| US-20040077706-A1 | Ligands for monoamine receptors and transporters, and methods of use thereof | AQUILA BRIAN M (US) | 2004-04-22 | — | — | US | disclosed |
| US-20030050309-A1 | Ligands for monoamine receptors and transporters, and methods of use thereof | SEPRACOR INC. | 2003-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080078-A1 | Method of treating addiction or dependence using a ligand for a monoamine receptor or transporter | PNMT, TAAR1, OPRL1 | SMN1; SMN2 3005/4885NPC1 1102/4885RAB9A 3636/4885 |
| US-20030050309-A1 | Ligands for monoamine receptors and transporters, and methods of use thereof | SLC6A2, OPRL1, SLC18A2 | SMN1; SMN2 872/4885NPC1 145/4885RAB9A 1348/4885 |
| US-20240279219-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | SMN1; SMN2 1943/4885NPC1 39/4885RAB9A 320/4885 |
| US-11492350-B2 | Compounds and methods of use | F12, C1R, ABCG2 | SMN1; SMN2 1943/4885NPC1 39/4885RAB9A 320/4885 |
| US-20230113778-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | SMN1; SMN2 1943/4885NPC1 39/4885RAB9A 320/4885 |
| US-20040077706-A1 | Ligands for monoamine receptors and transporters, and methods of use thereof | SLC6A2, OPRL1, SLC18A2 | SMN1; SMN2 872/4885NPC1 145/4885RAB9A 1348/4885 |
| US-12264154-B2 | Compounds and methods of use | F12, C1R, ABCG2 | SMN1; SMN2 1943/4885NPC1 39/4885RAB9A 320/4885 |
| US-12304907-B2 | Compounds and methods of use | F12, C1R, ABCG2 | SMN1; SMN2 1943/4885NPC1 39/4885RAB9A 320/4885 |
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | SMN1; SMN2 1943/4885NPC1 39/4885RAB9A 320/4885 |
| US-20090258901-A1 | LIGANDS FOR MONOAMINE RECEPTORS AND TRANSPORTERS, AND METHODS OF USE THEREOF | SLC6A2, OPRL1, SLC18A2 | SMN1; SMN2 872/4885NPC1 145/4885RAB9A 1348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.